Oncodesign Services
Oncodesign Services is a contract research organization (CRO) dedicated to pharmaceutical research, specializing in drug discovery, preclinical pharmacology, and advanced imaging. The company is committed to contributing to the discovery of innovative therapies against cancers and serious diseases with high medical needs. It offers a wide range of services including discovery, preclinical pharmacology, advanced imaging, and biologics development, with a focus on precision medicine, translational research, and supporting biotech innovation. Oncodesign aims to accelerate research programs and develop effective, affordable medicines through innovative solutions and collaborative efforts.
Industries
Nr. of Employees
large (251-1000)
Oncodesign Services
Dijon, Bourgogne, France, Europe
Services
Contract research programs that integrate target identification/validation, hit discovery, hit-to-lead, lead optimization and preclinical candidate selection delivered as coordinated multidisciplinary projects.
Preclinical proof-of-concept packages combining in vitro and ex vivo screening, early ADME, in vivo DMPK, bioanalytical method development, in vivo validation and imaging to accelerate candidate selection.
Imaging study execution and analysis for biodistribution, target engagement and treatment response using MRI, PET/MR, nuclear imaging and dosimetry services.
ADME profiling, drug metabolism studies, PK/PD study execution and bioanalytical method development including digital PCR, qPCR/RT-qPCR and GLP bioanalysis.
Small-molecule design and optimization services including SAR studies, fragment-based approaches and computer-assisted drug design workflows.
Conjugation chemistry and radiolabeling services to produce and evaluate radiopharmaceuticals, radiolabeled biologics and conjugates for biodistribution and efficacy testing.
Contract research programs that integrate target identification/validation, hit discovery, hit-to-lead, lead optimization and preclinical candidate selection delivered as coordinated multidisciplinary projects.
Preclinical proof-of-concept packages combining in vitro and ex vivo screening, early ADME, in vivo DMPK, bioanalytical method development, in vivo validation and imaging to accelerate candidate selection.
Imaging study execution and analysis for biodistribution, target engagement and treatment response using MRI, PET/MR, nuclear imaging and dosimetry services.
ADME profiling, drug metabolism studies, PK/PD study execution and bioanalytical method development including digital PCR, qPCR/RT-qPCR and GLP bioanalysis.
Small-molecule design and optimization services including SAR studies, fragment-based approaches and computer-assisted drug design workflows.
Conjugation chemistry and radiolabeling services to produce and evaluate radiopharmaceuticals, radiolabeled biologics and conjugates for biodistribution and efficacy testing.
Expertise Areas
- Integrated drug discovery (target-to-candidate; hit-to-lead and lead optimization)
- Preclinical pharmacology and efficacy studies
- Pharmaco-imaging and quantitative preclinical imaging
- DMPK, ADME and PK/PD
Key Technologies
- Magnetic resonance imaging (MRI)
- Simultaneous PET/MR and nuclear imaging
- Radiochemistry and radiolabeling
- Dosimetry analysis
News & Updates
Learn how humanized models advance oncology research. Watch the webinar to explore models, case studies, and actionable insights.
Oncodesign Services wins 'Oncology CRO of the Year 2025 – France' for the second year, highlighting excellence in drug discovery and preclinical oncology research.
Characterizing the inhibition of PRMT5:MTA by MRTX1719, a clinical stage MTAP-deleted cancer therapeutic.
Oncology CRO of the Year 2025 – France
Oncodesign Services wins 'Oncology CRO of the Year 2025 – France' for the second year, highlighting excellence in drug discovery and preclinical oncology research.
Learn how humanized models advance oncology research. Watch the webinar to explore models, case studies, and actionable insights.
Oncodesign Services wins 'Oncology CRO of the Year 2025 – France' for the second year, highlighting excellence in drug discovery and preclinical oncology research.
Characterizing the inhibition of PRMT5:MTA by MRTX1719, a clinical stage MTAP-deleted cancer therapeutic.
Oncology CRO of the Year 2025 – France
Oncodesign Services wins 'Oncology CRO of the Year 2025 – France' for the second year, highlighting excellence in drug discovery and preclinical oncology research.